Aclarion (NASDAQ:ACON – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04, Zacks reports. The business had revenue of $0.01 million for the quarter. Aclarion had a negative net margin of 10,246.33% and a negative return on equity of 2,554.98%.
Aclarion Stock Down 3.3 %
NASDAQ ACON opened at $0.22 on Friday. Aclarion has a 12 month low of $0.20 and a 12 month high of $9.90. The firm’s fifty day moving average price is $0.29 and its 200 day moving average price is $0.52.
Analyst Ratings Changes
Separately, Ascendiant Capital Markets assumed coverage on Aclarion in a report on Monday, July 29th. They set a “buy” rating and a $1.60 price target for the company.
Aclarion Company Profile
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.
Read More
- Five stocks we like better than Aclarion
- Airline Stocks – Top Airline Stocks to Buy Now
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- MarketBeat Week in Review – 8/12 – 8/16
- 10 Best Airline Stocks to Buy
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
-WOLF.png?v=2024-07-28&h=45&w=95&zc=2){kind=small}
